IntrinsicIntrinsic
← All summaries

AXON ENTERPRISE, INC.

AXON
Financials & Chart →

Business Summary

Axon Enterprise, Inc. is a technology company that provides integrated hardware and software solutions for customers across the public and private sector, including U.S. federal, state, and local governments, international governmental entities, commercial enterprises, and consumers. The company's products and services allow customers to capture and use critical data to support fully-connected operational workflows, with a trusted network that integrates software and hardware with connected devices including TASER energy devices, cameras and sensors, drones and robotics, cloud-based evidence management, records management, real-time operations software, critical incident and emergency response systems, immersive training, and productivity tools all enhanced by artificial intelligence. Axon's operations comprise a fully integrated suite of products across connected hardware, software, and services disclosed in two reportable segments: Software and Services and Connected Devices.

Axon's primary competitors are named across several product categories. In the body camera and in-car video industry, competitors include 10-8 Video Systems, 365Labs, Applied Concepts, Axis Communications, Coreforce, Digital Ally, Duress, Genetec, Getac, HALOS Body Cameras, Hikvision, Hytera, Insight LPR, IONODES, i-PRO, Kustom Signals, LensLock, Motorola Solutions, Tait Communications, Oracle, PatrolEyes, Pinnacle Response, Pro-Vision, Recoda, Reveal Media, Safe Fleet, Versaterm, Wireless CCTV, Wolfcom Enterprises, Wrap Technologies and Zepcam. In the records management system vertical, competitors include 365Labs, Beacon Software Solutions, Caliber Public Safety, Central Square Technologies, CivicEye, Coreforce, Core Technology Corporation, CSI Technology Group, EForce Software, Executive Information Services, Hexagon, LawSoft, Mark43, Motorola Solutions, Niche Technology, Oracle, Saab, SmartCop, Sopra Steria, Southern Software, Sun Ridge Systems, Tyler Technologies and Versaterm. In the conducted energy device market for professional users, competitors include Combined Systems, Inc., Byrna Technologies, Condor Non-Lethal Technologies, FN Herstal, PepperBall, SABRE Corporation, Mace Security International, UZI, Jolt, Wrap Technologies, B.E. Meyers & Co, Genasys, Monadnock, and Armament Systems and Procedures. Key competitive factors for TASER devices include accuracy, effectiveness, reputation, safety, cost, ease of use, and exceptional customer experience, with the design maturity of the TASER platform and the development and sale of a multi-shot device being key competitive differentiators.

Axon generates revenue from a combination of hardware sales, multi-year recurring software subscriptions, professional services, and extended warranties. Revenue is derived from two primary sources: SaaS offerings which include digital evidence management, productivity solutions, and real-time operations capabilities, and the sale of devices, accessories, and related extended warranties across the product portfolio which includes TASER, personal sensors, and platform solutions. The company offers to sell products and services on a standalone basis, but customers often prefer to bundle integrated hardware products and services together in a single transaction that allows them to make payments over a multi-year period. Annual recurring revenue totaled $1.3 billion as of December 31, 2025 . The financial strategy is to build highly recurring, highly profitable businesses and to drive growth through purposeful product innovation.

The Software and Services segment includes cloud-based SaaS solutions that deeply integrate with hardware to benefit customers and drive annual recurring revenue. These solutions are categorized into three areas: Digital Evidence Management, which includes Axon Evidence, a secure cloud-based platform for storing, managing and sharing critical evidence; Productivity Solutions, which includes Axon Records, Axon Standards, and a suite of solutions available under the AI Era Plan including Real-Time Translation, Draft One, Policy Chat, and Auto-Transcribe; and Real-time Operations, which includes Axon Respond, integrating location data, signal alerts and video feeds. This segment also includes non-recurring professional services revenue and revenue from certain on-premise software licenses.

The Connected Devices segment consists of hardware products that integrate with the software suite and includes three categories: TASER, which includes smart devices, tools and services for public safety officers and consumer personal protection, with revenue generated through device sales, cartridges, accessories, and extended warranties; Personal Sensors, which includes Axon Body cameras and accessories; and Platform Solutions, which includes Axon Fleet in-car video systems, fixed cameras, drone and counter-drone technology, virtual reality training hardware, and other devices that support operational awareness. Net sales for the Connected Devices segment were $1,576,864 thousand for the year ended December 31, 2025 , compared to $1,221,292 thousand for the year ended December 31, 2024 . Net sales for the Software and Services segment were $1,202,672 thousand for the year ended December 31, 2025 , compared to $861,234 thousand for the year ended December 31, 2024 .

During the year ended December 31, 2025, Axon realigned its business into two reportable segments, Connected Devices and Software and Services. In March 2025, the company issued $1.0 billion aggregate principal amount of Senior Notes due 2030 and $750.0 million aggregate principal amount of Senior Notes due 2033 . During the year ended December 31, 2025, the company sold approximately 0.7 million shares of its common stock under its at-the-market equity offering program, generating approximately $494.7 million in aggregate gross proceeds and recording aggregate net proceeds of $489.4 million in additional paid-in capital after deducting related expenses including commissions and issuance costs of $5.3 million . The company entered into exchange agreements with certain holders of the 2027 Notes to exchange approximately $604.3 million aggregate principal amount for consideration consisting of cash and shares of common stock, recognizing an aggregate inducement expense of $38.9 million . Subsequent to year end, the company acquired Carbyne Ltd. for a base purchase price of $625.0 million . As of December 31, 2025, the company had more than 5,100 full-time employees and more than 1,200 temporary employees , with full-time employees increasing by approximately 1,000 or 24% during 2025.

Total revenues for the year ended December 31, 2025 were $2,779,536 thousand , an increase of $697,010 thousand or 33.5% from $2,082,526 thousand for the year ended December 31, 2024. Gross margin dollars increased $416,726 thousand and gross margin as a percentage of revenue was 59.7% compared to 59.6% in the prior year. Adjusted gross margin decreased to 62.6% for the year ended December 31, 2025 compared to 63.2% for the year ended December 31, 2024. Net income was $124,656 thousand for the year ended December 31, 2025, compared to $377,034 thousand for the year ended December 31, 2024. Net income per diluted share was $1.51 for the year ended December 31, 2025, compared to $4.80 for the year ended December 31, 2024.

Business Outlook

Axon's growth strategy is centered on developing new products and product features that achieve market acceptance in a timely and cost-effective manner, with significant resources devoted to developing and deploying SaaS solutions to a large number of customers. The company's SaaS solutions are designed to drive annual recurring revenue, which totaled $1.3 billion as of December 31, 2025 . The company's financial strategy is to build highly recurring, highly profitable businesses and to drive growth through purposeful product innovation. The company is investing in sales personnel and strategic headcount additions to support growth as it diversifies into new markets. The company's research and development investments support continuous innovation on behalf of customers, with R&D expenses of $684,308 thousand for the year ended December 31, 2025, an increase of $242,715 thousand or 55.0% from the prior year.

The company's growth is also driven by acquisitions and investments in complementary products, technologies, or businesses. Subsequent to the year ended December 31, 2025, the company acquired Carbyne Ltd., a leading cloud-native emergency communications and response platform, for a base purchase price of $625.0 million , funded using available cash on-hand. The company's emergency communications solutions compete with both over-the-top data and AI platforms that integrate with incumbent 911 infrastructure and with more fully integrated Next Generation 911 platforms, and the acquisition of Carbyne extends offerings more deeply into the core call-handling layer of the NG911 workflow.

The filing discusses margin trajectory primarily through the lens of adjusted gross margin, which decreased to 62.6% for the year ended December 31, 2025 compared to 63.2% for the year ended December 31, 2024, driven by global tariffs and a higher mix of Platform Solutions revenue. Gross margin for the Connected Devices segment decreased to 48.7% from 49.4% , and adjusted gross margin for the Connected Devices segment was 51.2% compared to 53.6% in the prior year, driven by higher mix of Platform Solutions revenue and global tariffs. Gross margin for the Software and Services segment decreased to 74.0% from 74.1% , while adjusted gross margin for the Software and Services segment increased to 77.5% from 76.8% , driven by higher software mix. Operating expenses increased by $537,361 thousand , reflecting increased headcount to support business growth and stock-based compensation expense.

The company performs manufacturing, final assembly and final test operations at its facilities in Arizona and owns substantially all of the equipment required to develop, prototype, manufacture and assemble finished products. The company has continued to maintain both its ISO 9001 and ISO 9001:2015 certifications. The company purchases many components and raw materials from numerous suppliers in various countries and continuously monitors its supply chain, identifies alternate shipping and logistic sources, and works with foreign regulators so suppliers can provide high quality parts. The company has programs to hold additional materials such as resins, battery components, major semiconductors and other critical components to mitigate supply interruptions and better manage costs. As of December 31, 2025, the company had more than 5,100 full-time employees and more than 1,200 temporary employees , with full-time employees increasing by approximately 1,000 or 24% during 2025, primarily in sales and R&D organizations.

Research and development spending was $684,308 thousand for the year ended December 31, 2025, compared to $441,593 thousand for the year ended December 31, 2024. Capital expenditures for purchases of property and equipment were $136,258 thousand for the year ended December 31, 2025, compared to $78,785 thousand for the year ended December 31, 2024. In February 2016, the Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of outstanding common stock, and as of December 31, 2025, $16.3 million remained available under the plan for future purchases. The company has not declared or paid cash dividends on its common stock and does not intend to pay cash dividends in the foreseeable future.

The company faces structural headwinds including substantial dependence on continued acceptance of products and services by law enforcement agencies worldwide, with any reduction in demand potentially materially adversely affecting the business. The company substantially depends on sales of its CEDs, and if these products do not continue to be widely accepted, growth prospects, operating results and financial condition will be diminished. The company faces risks associated with rapid technological change and new competing products, particularly as AI and machine learning technologies are rapidly developing and incorporated into products and customer operations. Negative publicity could adversely impact sales, which could cause revenues or operating results to decline. The company also faces risks from unavailability of materials or higher costs, with dependence on U.S. domestic and international suppliers for components used in assembly of products, including single or sole-source components.

Geographic and regulatory constraints identified by management include risks associated with international operations, including restrictions on foreign ownership and investments, foreign exchange controls, import and export requirements, tariffs, evolving interpretations and enforcement of U.S. Customs and Border Protection regulations and trade laws, trade disputes, product certification mandates, sanctions, foreign regulatory requirements, and government-imposed supplier restrictions. The company's CEDs are subject to federal, state, local, and international laws affecting classification, sale, export, and use, with the TASER 10 CED classified as a firearm under the Gun Control Act of 1968, requiring the company to maintain a federal firearms license. The company is subject to evolving U.S. and foreign laws governing the collection, processing, storage, and transfer of personal and sensitive information, as well as the development and deployment of AI systems, with the European Union's General Data Protection Regulation and AI Act imposing compliance obligations.

Risk Factors

Axon substantially depends on continued acceptance of its products and services by law enforcement agencies worldwide, and any reduction in demand could materially adversely affect the business. The company substantially depends on sales of its CEDs, and if these products do not continue to be widely accepted, growth prospects, operating results and financial condition will be diminished. The company faces risks associated with rapid technological change and new competing products, particularly as AI and machine learning technologies are rapidly developing. The company is subject to personal injury, wrongful death, product liability and other liability claims, and is self-insured for the first $5.0 million of any product claim made after 2014. The company faces risks related to its indebtedness, with an aggregate of $1.75 billion of Senior Notes outstanding as of December 31, 2025 , and the indentures governing the 2030 Notes and 2033 Notes impose restrictions on the company's ability to incur additional debt and liens, make distributions to shareholders in certain circumstances, dispose of assets and enter into mergers, consolidations and transfers of all or substantially all of assets. The company has identified a material weakness in internal control over financial reporting related to revenue recognition as of December 31, 2025 , which if not successfully remediated could adversely affect the accuracy and timing of financial reporting and investor confidence.

Management Priorities

Management's message emphasizes that Axon is a technology company providing integrated hardware and software solutions, founder-led since 1993, with a mission to protect life. The company's integrated technology platform of hardware and software solutions advances the mission to make the bullet obsolete, reduce social conflict, and enable a fair and effective justice system. Management highlights that the company's financial strategy is to build highly recurring, highly profitable businesses and to drive growth through purposeful product innovation. The strategic priorities emphasized for the period ahead include continuing to invest in research and development to support continuous innovation, expanding internationally across Europe, Asia, and the Americas to drive the mission globally, and investing in sales personnel and strategic headcount additions to support growth in new markets. Management notes that the company's regrettable attrition rate was less than 1.0% , below the annual goal of 1.0% , and that employees reported a higher than 88% satisfaction score for feeling proud to work at Axon during the 2025 employee engagement survey and an 84% satisfaction score on recommending Axon as a great place to work.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Key Product Category Revenue Drivers
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Liquidity and Capital Resources
  7. [7] Item 7, MD&A — Liquidity and Capital Resources
  8. [8] Item 7, MD&A — Liquidity and Capital Resources
  9. [9] Item 7, MD&A — Liquidity and Capital Resources
  10. [10] Item 7, MD&A — Liquidity and Capital Resources
  11. [11] Item 8, Note 10 — Notes Payable, Net
  12. [12] Item 8, Note 10 — Notes Payable, Net
  13. [13] Item 7, MD&A — Liquidity and Capital Resources
  14. [14] Item 1, Business — Human Capital Resources
  15. [15] Item 1, Business — Human Capital Resources
  16. [16] Item 1, Business — Human Capital Resources
  17. [17] Item 7, MD&A — Overview
  18. [18] Item 7, MD&A — Overview
  19. [19] Item 7, MD&A — Overview
  20. [20] Item 7, MD&A — Overview
  21. [21] Item 7, MD&A — Overview
  22. [22] Item 7, MD&A — Overview
  23. [23] Item 7, MD&A — Overview
  24. [24] Item 7, MD&A — Overview
  25. [25] Item 7, MD&A — Overview
  26. [26] Item 7, MD&A — Overview
  27. [27] Item 7, MD&A — Net Income
  28. [28] Item 7, MD&A — Net Income
  29. [29] Item 1, Business — Key Product Category Revenue Drivers
  30. [30] Item 7, MD&A — Research and Development Expenses
  31. [31] Item 7, MD&A — Research and Development Expenses
  32. [32] Item 7, MD&A — Liquidity and Capital Resources
  33. [33] Item 7, MD&A — Overview
  34. [34] Item 7, MD&A — Overview
  35. [35] Item 7, MD&A — Gross Margin
  36. [36] Item 7, MD&A — Gross Margin
  37. [37] Item 7, MD&A — Gross Margin
  38. [38] Item 7, MD&A — Gross Margin
  39. [39] Item 7, MD&A — Gross Margin
  40. [40] Item 7, MD&A — Gross Margin
  41. [41] Item 7, MD&A — Gross Margin
  42. [42] Item 7, MD&A — Gross Margin
  43. [43] Item 7, MD&A — Overview
  44. [44] Item 1, Business — Human Capital Resources
  45. [45] Item 1, Business — Human Capital Resources
  46. [46] Item 1, Business — Human Capital Resources
  47. [47] Item 7, MD&A — Research and Development Expenses
  48. [48] Item 7, MD&A — Research and Development Expenses
  49. [49] Item 8, Consolidated Statements of Cash Flows
  50. [50] Item 8, Consolidated Statements of Cash Flows
  51. [51] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  52. [52] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  53. [53] Item 8, Note 11 — Commitments and Contingencies
  54. [54] Item 7, MD&A — Liquidity and Capital Resources
  55. [55] Item 9A, Controls and Procedures
  56. [56] Item 1, Business — Human Capital Resources
  57. [57] Item 1, Business — Human Capital Resources
  58. [58] Item 1, Business — Human Capital Resources
  59. [59] Item 1, Business — Human Capital Resources
  60. [60] Item 8, Consolidated Statements of Operations and Comprehensive Income
  61. [61] Item 8, Consolidated Statements of Operations and Comprehensive Income
  62. [62] Item 8, Consolidated Statements of Operations and Comprehensive Income
  63. [63] Item 8, Consolidated Statements of Operations and Comprehensive Income
  64. [64] Item 8, Consolidated Statements of Operations and Comprehensive Income
  65. [65] Item 8, Consolidated Statements of Operations and Comprehensive Income
  66. [66] Item 8, Consolidated Statements of Operations and Comprehensive Income
  67. [67] Item 8, Consolidated Statements of Operations and Comprehensive Income
  68. [68] Item 7, MD&A — Overview
  69. [69] Item 7, MD&A — Overview
  70. [70] Item 8, Consolidated Statements of Cash Flows
  71. [71] Item 8, Consolidated Statements of Cash Flows
  72. [72] Item 8, Consolidated Balance Sheets
  73. [73] Item 8, Consolidated Balance Sheets
  74. [74] Item 7, MD&A — Liquidity and Capital Resources
  75. [75] Item 7, MD&A — Liquidity and Capital Resources
  76. [76] Item 7, MD&A — Other Income, Net
  77. [77] Item 7, MD&A — Provision for Income Taxes
  78. [78] Item 7, MD&A — Other Income, Net
  79. [79] Item 7, MD&A — Other Income, Net
  80. [80] Item 7, MD&A — Interest Income (Loss), Net
  81. [81] Item 7, MD&A — Net Sales
  82. [82] Item 7, MD&A — Gross Margin
  83. [83] Item 7, MD&A — Net Sales
  84. [84] Item 7, MD&A — Gross Margin

Analysis on 6/8/2026